| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testosterone | 78 | 2025 | 558 | 15.710 |
Why?
|
| Erectile Dysfunction | 38 | 2025 | 198 | 13.180 |
Why?
|
| Hypogonadism | 51 | 2024 | 296 | 12.940 |
Why?
|
| Hormone Replacement Therapy | 37 | 2025 | 200 | 8.350 |
Why?
|
| Prostatic Neoplasms | 33 | 2025 | 1549 | 5.880 |
Why?
|
| Penile Prosthesis | 11 | 2024 | 38 | 4.220 |
Why?
|
| Androgens | 17 | 2021 | 279 | 4.180 |
Why?
|
| Penile Implantation | 8 | 2024 | 24 | 3.790 |
Why?
|
| Prostatectomy | 20 | 2022 | 344 | 2.770 |
Why?
|
| Prostate-Specific Antigen | 13 | 2025 | 255 | 2.380 |
Why?
|
| Penile Induration | 5 | 2024 | 37 | 2.350 |
Why?
|
| Penile Erection | 16 | 2023 | 82 | 2.340 |
Why?
|
| Cardiovascular Diseases | 20 | 2025 | 1960 | 2.250 |
Why?
|
| Male | 132 | 2025 | 61573 | 2.160 |
Why?
|
| Sexual Dysfunction, Physiological | 7 | 2024 | 83 | 1.660 |
Why?
|
| Libido | 5 | 2022 | 36 | 1.650 |
Why?
|
| Patient Satisfaction | 9 | 2025 | 474 | 1.590 |
Why?
|
| Stem Cell Transplantation | 3 | 2024 | 233 | 1.560 |
Why?
|
| Penis | 10 | 2025 | 100 | 1.470 |
Why?
|
| Humans | 136 | 2025 | 125331 | 1.460 |
Why?
|
| Urology | 4 | 2024 | 79 | 1.370 |
Why?
|
| Sexual Behavior | 9 | 2024 | 246 | 1.250 |
Why?
|
| Depression | 5 | 2018 | 1237 | 1.060 |
Why?
|
| Aged | 43 | 2025 | 19728 | 0.990 |
Why?
|
| Middle Aged | 48 | 2025 | 26807 | 0.940 |
Why?
|
| Holistic Health | 1 | 2025 | 11 | 0.940 |
Why?
|
| Finasteride | 2 | 2022 | 20 | 0.930 |
Why?
|
| Platelet-Rich Plasma | 1 | 2024 | 15 | 0.920 |
Why?
|
| Microbial Collagenase | 1 | 2024 | 12 | 0.920 |
Why?
|
| Watchful Waiting | 1 | 2025 | 69 | 0.910 |
Why?
|
| Sexual Health | 1 | 2024 | 9 | 0.880 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 22 | 0.870 |
Why?
|
| Androgen Antagonists | 2 | 2024 | 120 | 0.870 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2025 | 108 | 0.860 |
Why?
|
| Health Care Costs | 3 | 2018 | 372 | 0.860 |
Why?
|
| Reproductive Health | 1 | 2024 | 41 | 0.850 |
Why?
|
| Prosthesis Design | 4 | 2024 | 668 | 0.780 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2021 | 4 | 0.760 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2021 | 31 | 0.750 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2021 | 14 | 0.740 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 282 | 0.730 |
Why?
|
| Surveys and Questionnaires | 12 | 2025 | 3741 | 0.730 |
Why?
|
| Cystic Fibrosis | 1 | 2024 | 258 | 0.720 |
Why?
|
| Telemedicine | 2 | 2024 | 439 | 0.700 |
Why?
|
| Polycythemia | 1 | 2020 | 44 | 0.680 |
Why?
|
| Treatment Outcome | 23 | 2024 | 12290 | 0.680 |
Why?
|
| Eunuchism | 2 | 2022 | 7 | 0.670 |
Why?
|
| Retrospective Studies | 23 | 2025 | 16344 | 0.650 |
Why?
|
| Adult | 33 | 2025 | 29607 | 0.630 |
Why?
|
| Curriculum | 1 | 2024 | 726 | 0.630 |
Why?
|
| Fertility | 2 | 2018 | 259 | 0.620 |
Why?
|
| Prostate | 4 | 2023 | 436 | 0.610 |
Why?
|
| Clomiphene | 1 | 2018 | 12 | 0.610 |
Why?
|
| North America | 7 | 2024 | 242 | 0.600 |
Why?
|
| Spinal Cord Injuries | 3 | 2007 | 313 | 0.590 |
Why?
|
| Botulinum Toxins, Type A | 3 | 2005 | 167 | 0.580 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2017 | 60 | 0.560 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 76 | 0.550 |
Why?
|
| Societies, Medical | 5 | 2024 | 700 | 0.550 |
Why?
|
| Varicocele | 4 | 2010 | 60 | 0.520 |
Why?
|
| Quality of Life | 7 | 2024 | 1946 | 0.520 |
Why?
|
| Prospective Studies | 12 | 2025 | 6160 | 0.500 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 257 | 0.500 |
Why?
|
| Abdominal Wall | 1 | 2015 | 33 | 0.480 |
Why?
|
| Postoperative Complications | 7 | 2024 | 3055 | 0.470 |
Why?
|
| Impotence, Vasculogenic | 2 | 2014 | 9 | 0.460 |
Why?
|
| Comorbidity | 7 | 2018 | 1531 | 0.460 |
Why?
|
| Drug Implants | 5 | 2015 | 42 | 0.450 |
Why?
|
| Men's Health | 3 | 2024 | 20 | 0.450 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 86 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 1117 | 0.440 |
Why?
|
| United States | 18 | 2023 | 10922 | 0.430 |
Why?
|
| Prostatic Hyperplasia | 3 | 2023 | 119 | 0.430 |
Why?
|
| Urinary Bladder | 2 | 2005 | 244 | 0.430 |
Why?
|
| Medication Adherence | 1 | 2018 | 400 | 0.420 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2013 | 43 | 0.420 |
Why?
|
| Pandemics | 1 | 2021 | 1112 | 0.420 |
Why?
|
| Extracorporeal Shockwave Therapy | 2 | 2024 | 9 | 0.410 |
Why?
|
| Registries | 9 | 2018 | 1431 | 0.400 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 24 | 0.400 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 426 | 0.390 |
Why?
|
| Carcinoma | 1 | 2015 | 290 | 0.390 |
Why?
|
| Urologic Diseases | 2 | 2023 | 44 | 0.380 |
Why?
|
| Brachytherapy | 1 | 2012 | 75 | 0.380 |
Why?
|
| Klinefelter Syndrome | 1 | 2011 | 17 | 0.380 |
Why?
|
| Aging | 2 | 2016 | 1182 | 0.370 |
Why?
|
| Deficiency Diseases | 1 | 2011 | 11 | 0.360 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 52 | 0.360 |
Why?
|
| Heart Diseases | 1 | 2016 | 496 | 0.360 |
Why?
|
| Coitus | 2 | 2025 | 20 | 0.360 |
Why?
|
| Patient Compliance | 2 | 2011 | 472 | 0.350 |
Why?
|
| Risk Factors | 12 | 2021 | 10287 | 0.340 |
Why?
|
| Public Health | 1 | 2012 | 266 | 0.340 |
Why?
|
| Aged, 80 and over | 12 | 2023 | 6555 | 0.340 |
Why?
|
| Nitric Oxide | 1 | 2013 | 485 | 0.330 |
Why?
|
| Prevalence | 4 | 2018 | 2466 | 0.330 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 340 | 0.320 |
Why?
|
| Medicare | 5 | 2023 | 428 | 0.320 |
Why?
|
| Urologic Surgical Procedures, Male | 3 | 2019 | 36 | 0.310 |
Why?
|
| Cardiovascular System | 3 | 2021 | 107 | 0.310 |
Why?
|
| Mass Screening | 1 | 2015 | 785 | 0.310 |
Why?
|
| Estradiol | 4 | 2021 | 530 | 0.310 |
Why?
|
| Disease Progression | 3 | 2025 | 2081 | 0.290 |
Why?
|
| Administration, Oral | 3 | 2025 | 681 | 0.290 |
Why?
|
| Operative Time | 3 | 2018 | 165 | 0.280 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2015 | 1242 | 0.280 |
Why?
|
| Gels | 4 | 2023 | 69 | 0.280 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2371 | 0.280 |
Why?
|
| Receptors, Epoprostenol | 1 | 2007 | 15 | 0.270 |
Why?
|
| Databases, Factual | 3 | 2023 | 1174 | 0.270 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2007 | 28 | 0.260 |
Why?
|
| Linear Models | 3 | 2013 | 687 | 0.260 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2007 | 47 | 0.260 |
Why?
|
| Behavior Therapy | 2 | 2023 | 256 | 0.260 |
Why?
|
| Incidence | 5 | 2021 | 3134 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 729 | 0.260 |
Why?
|
| Urinary Incontinence | 1 | 2006 | 70 | 0.250 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 276 | 0.250 |
Why?
|
| Sensation | 1 | 2005 | 57 | 0.240 |
Why?
|
| Neurotoxins | 1 | 2005 | 56 | 0.240 |
Why?
|
| Mice, Nude | 2 | 2017 | 725 | 0.230 |
Why?
|
| Sexology | 1 | 2024 | 3 | 0.230 |
Why?
|
| Network Meta-Analysis | 1 | 2024 | 28 | 0.230 |
Why?
|
| Urethral Stricture | 1 | 2004 | 13 | 0.230 |
Why?
|
| Spermatogenesis | 2 | 2018 | 173 | 0.230 |
Why?
|
| Injections, Intralesional | 1 | 2024 | 48 | 0.230 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 3415 | 0.230 |
Why?
|
| Rats | 6 | 2020 | 3725 | 0.230 |
Why?
|
| Animals | 11 | 2023 | 34298 | 0.230 |
Why?
|
| Cosmetic Techniques | 1 | 2024 | 11 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1270 | 0.220 |
Why?
|
| Female | 12 | 2024 | 66836 | 0.220 |
Why?
|
| Blood Pressure | 3 | 2021 | 1375 | 0.220 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 44 | 0.220 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 280 | 0.220 |
Why?
|
| Urinary Retention | 1 | 2023 | 18 | 0.220 |
Why?
|
| Health Expenditures | 2 | 2016 | 103 | 0.220 |
Why?
|
| Neuromuscular Agents | 1 | 2004 | 67 | 0.210 |
Why?
|
| Alprostadil | 2 | 2016 | 27 | 0.210 |
Why?
|
| Patient Preference | 1 | 2025 | 118 | 0.210 |
Why?
|
| Bayes Theorem | 1 | 2024 | 285 | 0.210 |
Why?
|
| Neurocognitive Disorders | 1 | 2024 | 68 | 0.210 |
Why?
|
| Time Factors | 4 | 2024 | 6318 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 1270 | 0.200 |
Why?
|
| Receptors, Androgen | 3 | 2014 | 414 | 0.200 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 728 | 0.200 |
Why?
|
| Priapism | 1 | 2022 | 10 | 0.200 |
Why?
|
| Sildenafil Citrate | 2 | 2013 | 55 | 0.200 |
Why?
|
| Insurance Coverage | 1 | 2023 | 120 | 0.190 |
Why?
|
| Life Style | 1 | 2025 | 416 | 0.190 |
Why?
|
| Biopsy | 1 | 2025 | 1241 | 0.180 |
Why?
|
| Young Adult | 8 | 2021 | 9066 | 0.180 |
Why?
|
| Orchiectomy | 2 | 2017 | 51 | 0.170 |
Why?
|
| Traction | 1 | 2019 | 9 | 0.160 |
Why?
|
| Azoospermia | 2 | 2010 | 46 | 0.160 |
Why?
|
| Placenta | 1 | 2023 | 507 | 0.160 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2016 | 33 | 0.160 |
Why?
|
| Regenerative Medicine | 1 | 2019 | 31 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2019 | 240 | 0.150 |
Why?
|
| Dementia | 1 | 2024 | 451 | 0.150 |
Why?
|
| Lipids | 3 | 2023 | 522 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 140 | 0.150 |
Why?
|
| Reoperation | 1 | 2021 | 829 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 331 | 0.150 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2018 | 64 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2020 | 168 | 0.150 |
Why?
|
| Hematocrit | 2 | 2021 | 114 | 0.150 |
Why?
|
| Chorionic Gonadotropin | 1 | 2018 | 79 | 0.150 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 104 | 0.150 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2014 | 40 | 0.150 |
Why?
|
| Double-Blind Method | 3 | 2023 | 1634 | 0.140 |
Why?
|
| Health Status | 2 | 2010 | 378 | 0.140 |
Why?
|
| Exercise | 1 | 2023 | 815 | 0.140 |
Why?
|
| Caffeine | 1 | 2018 | 71 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1534 | 0.140 |
Why?
|
| Recovery of Function | 4 | 2022 | 443 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2017 | 231 | 0.130 |
Why?
|
| Gene Expression | 1 | 2021 | 1553 | 0.130 |
Why?
|
| Diabetes Complications | 2 | 2015 | 203 | 0.130 |
Why?
|
| Dosage Forms | 1 | 2016 | 9 | 0.130 |
Why?
|
| Administration, Cutaneous | 2 | 2013 | 66 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 263 | 0.130 |
Why?
|
| Thrombosis | 1 | 2021 | 519 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2020 | 4837 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 5166 | 0.120 |
Why?
|
| Fasciotomy | 1 | 2015 | 27 | 0.120 |
Why?
|
| Personal Satisfaction | 2 | 2013 | 104 | 0.120 |
Why?
|
| Age Distribution | 1 | 2016 | 417 | 0.120 |
Why?
|
| Endothelium, Vascular | 2 | 2017 | 491 | 0.120 |
Why?
|
| Heterografts | 1 | 2015 | 175 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 145 | 0.120 |
Why?
|
| Heart Rate | 1 | 2017 | 592 | 0.120 |
Why?
|
| Vulvodynia | 1 | 2014 | 2 | 0.120 |
Why?
|
| Biomarkers | 2 | 2015 | 3093 | 0.120 |
Why?
|
| Luteinizing Hormone | 4 | 2015 | 131 | 0.120 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 36 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 511 | 0.120 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 19 | 0.120 |
Why?
|
| Endocrinology | 1 | 2017 | 134 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 914 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2015 | 267 | 0.110 |
Why?
|
| Nanostructures | 1 | 2014 | 50 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3309 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2015 | 384 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2015 | 117 | 0.110 |
Why?
|
| Reproduction | 1 | 2016 | 237 | 0.110 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2013 | 26 | 0.110 |
Why?
|
| Bone Density | 1 | 2016 | 319 | 0.110 |
Why?
|
| Postoperative Period | 3 | 2022 | 335 | 0.110 |
Why?
|
| Nitric Oxide Synthase | 2 | 2016 | 176 | 0.110 |
Why?
|
| Streptozocin | 1 | 2013 | 24 | 0.110 |
Why?
|
| Microspheres | 1 | 2013 | 70 | 0.100 |
Why?
|
| Infertility, Male | 2 | 2015 | 281 | 0.100 |
Why?
|
| Adolescent | 5 | 2022 | 19419 | 0.100 |
Why?
|
| Disease Management | 1 | 2017 | 531 | 0.100 |
Why?
|
| Body Composition | 1 | 2016 | 521 | 0.100 |
Why?
|
| Sulfones | 1 | 2013 | 74 | 0.100 |
Why?
|
| Decision Making | 1 | 2018 | 657 | 0.100 |
Why?
|
| Purines | 1 | 2013 | 116 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 141 | 0.100 |
Why?
|
| Health Surveys | 2 | 2011 | 245 | 0.100 |
Why?
|
| Pregnancy | 2 | 2023 | 7219 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2014 | 155 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 198 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2021 | 3439 | 0.100 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 137 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2016 | 1397 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 434 | 0.100 |
Why?
|
| Tadalafil | 1 | 2011 | 4 | 0.090 |
Why?
|
| Piperazines | 1 | 2013 | 242 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2013 | 309 | 0.090 |
Why?
|
| Prosthesis-Related Infections | 1 | 2013 | 175 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 818 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 731 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2016 | 641 | 0.090 |
Why?
|
| Muscle Contraction | 2 | 2016 | 188 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1018 | 0.090 |
Why?
|
| Sexual Partners | 1 | 2011 | 87 | 0.090 |
Why?
|
| Logistic Models | 2 | 2018 | 1808 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 171 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2005 | 1189 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2018 | 1562 | 0.090 |
Why?
|
| Risk | 1 | 2012 | 759 | 0.090 |
Why?
|
| Cause of Death | 1 | 2012 | 472 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2011 | 240 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 124 | 0.080 |
Why?
|
| Sexuality | 1 | 2009 | 15 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1174 | 0.080 |
Why?
|
| Organ Size | 1 | 2010 | 441 | 0.080 |
Why?
|
| Mice | 2 | 2017 | 17736 | 0.080 |
Why?
|
| Program Development | 1 | 2010 | 185 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 595 | 0.080 |
Why?
|
| Patient Safety | 1 | 2014 | 398 | 0.080 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2009 | 6 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 202 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2012 | 1493 | 0.080 |
Why?
|
| Age Factors | 4 | 2019 | 2824 | 0.080 |
Why?
|
| Evidence-Based Medicine | 3 | 2017 | 631 | 0.080 |
Why?
|
| Veins | 1 | 2009 | 105 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3431 | 0.070 |
Why?
|
| Laparoscopy | 2 | 2013 | 490 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2010 | 353 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 408 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 216 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2010 | 1253 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4405 | 0.070 |
Why?
|
| Sex Factors | 1 | 2010 | 1282 | 0.070 |
Why?
|
| International Cooperation | 2 | 2017 | 157 | 0.060 |
Why?
|
| Masturbation | 1 | 2025 | 2 | 0.060 |
Why?
|
| Recurrence | 2 | 2009 | 1391 | 0.060 |
Why?
|
| Constriction | 1 | 2025 | 50 | 0.060 |
Why?
|
| Urothelium | 1 | 2004 | 60 | 0.060 |
Why?
|
| Retreatment | 1 | 2004 | 89 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 554 | 0.060 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2015 | 187 | 0.060 |
Why?
|
| Transdermal Patch | 1 | 2023 | 7 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 2906 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2022 | 38 | 0.050 |
Why?
|
| Testosterone Congeners | 1 | 2022 | 15 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2022 | 26 | 0.050 |
Why?
|
| Monitoring, Ambulatory | 1 | 2021 | 55 | 0.050 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 155 | 0.050 |
Why?
|
| HIV Infections | 1 | 2013 | 1894 | 0.040 |
Why?
|
| SEER Program | 1 | 2021 | 202 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 295 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2018 | 89 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 150 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 79 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2017 | 40 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1275 | 0.030 |
Why?
|
| Survival Rate | 1 | 2022 | 2046 | 0.030 |
Why?
|
| Premature Ejaculation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Child | 3 | 2022 | 24575 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 295 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 136 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1358 | 0.030 |
Why?
|
| Patient Participation | 1 | 2018 | 220 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 1043 | 0.030 |
Why?
|
| Stroke | 1 | 2023 | 979 | 0.030 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2014 | 4 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2014 | 12 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 56 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 2014 | 109 | 0.030 |
Why?
|
| Manometry | 1 | 2014 | 57 | 0.030 |
Why?
|
| Patient Admission | 1 | 2015 | 185 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2014 | 43 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 188 | 0.030 |
Why?
|
| Arteries | 1 | 2014 | 218 | 0.030 |
Why?
|
| Canada | 1 | 2013 | 286 | 0.030 |
Why?
|
| Kinetics | 1 | 2014 | 1332 | 0.020 |
Why?
|
| Robotics | 1 | 2013 | 108 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1104 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 42 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 717 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 696 | 0.020 |
Why?
|
| Affect | 1 | 2011 | 157 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 1617 | 0.020 |
Why?
|
| Ligation | 1 | 2009 | 131 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2569 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2009 | 180 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1632 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 589 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 341 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 809 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 1133 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 2249 | 0.010 |
Why?
|